Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to -$45.4 million.

  • Pharming's EPS (Basic) changed N/A to -$45.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$45.4 million, marking a year-over-year change of. This contributed to the annual value of -$46.6 million for FY2024, which is 29128874990000.0% down from last year.
  • As of Q4 2024, Pharming's EPS (Basic) stood at -$45.4 million.
  • In the past 5 years, Pharming's EPS (Basic) registered a high of $624131.4 during Q4 2021, and its lowest value of -$108.0 million during Q2 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$7.9 million (2021), whereas its average is -$20.6 million.
  • As far as peak fluctuations go, Pharming's EPS (Basic) skyrocketed by 17570.95% in 2021, and later crashed by 28286231.64% in 2022.
  • Over the past 5 years, Pharming's EPS (Basic) (Quarter) stood at -$824377.1 in 2020, then soared by 175.71% to $624131.4 in 2021, then crashed by 1789.49% to -$10.5 million in 2022, then plummeted by 294.87% to -$41.6 million in 2023, then fell by 9.12% to -$45.4 million in 2024.
  • Its EPS (Basic) stands at -$45.4 million for Q4 2024, versus -$41.6 million for Q3 2023 and -$108.0 million for Q2 2023.